Recent scientific developments in medicine have the potential to cure or fundamentally modify previously incurable or poorly treated diseases and conditions, relieving the suffering of patients and ...

Drug value assessments generally fail to account for the complexities of health care systems and thus can misinform price negotiations and lead to overly restrictive access policies. Studies have ...

There are shortcomings in the ways we have approached value assessment to date, writes the executive director of the Innovation and Value Initiative. Jennifer Bright is the executive director of the ...

Much of the biopharmaceutical industry this week is focused on the J.P. Morgan Healthcare Conference (JPM), where business leaders are investing in science and technologies with the potential to ...

When it comes to determining value, the U.S. health care system faces unique challenges. Without a better approach, the twin goals of continued innovation and broad-based drug affordability will be ...

Trying to gauge the value of new drugs and devices is becoming increasingly important in the U.S. health care system, something that other countries have done explicitly for years. Pressure to get ...

Julia Kagan is a financial/consumer journalist and former senior editor, personal finance, of Investopedia. Doretha Clemons, Ph.D., MBA, PMP, has been a corporate IT executive and professor for 34 ...